ONLINE SUPPLEMENTARY TABLES

Table S1

Rates of serious adverse events (all) and adverse events (at least 5 % in one of the study groups) reported for the included studies investigating d-cycloserine (listed by frequency).

D-Cycloserine			
	RCTs		**OLTs**
	(Farrell et al., 2013; Storch et al., 2010)		(Posey et al., 2004)
	Drug	**Plc**	**Drug**
Total N	**24**	**23**	**12**
	n (%)	**n (%)**	**n (%)**
Serious adverse events			
-	-	-	-
Adverse events			
Increased echolalia	-	-	1 (8.3)
Transient motor tic	-	-	1 (8.3)

Abbreviations: OLTs: Open-label trials; Plc: placebo; RCTs: randomized controlled trials.

Table S2

Rates of serious adverse events (all) and adverse events (at least 5 % in one of the study groups) reported for the included studies investigating memantine (listed by frequency).

Memantine			
	RCTs		**OLTs**
	(Ghaleiha, Asadabadi, et al., 2013; Hardan, 2014; Hendren, 2014)		(Chez et al., 2007; Owley et al., 2006), (Erickson et al., 2007; Findling et al., 2007; Melmed, 2014)
	Drug	**Plc**	**Drug**
Total N	**400**	**240**	**1106**
	n (%)	**n (%)**	**n (%)**
Serious adverse events			
Not further specified	-	-	6 (0.5)
Adverse events			
Headache	-	-	80 (7.2)
Nasopharyngitis	-	-	59 (5.3)

Abbreviations: OLTs: O-label trials; Plc: placebo; RCTs: randomized controlled trials.

Table S3

Rates of serious adverse events (all) and adverse events (at least 5 % in one of the study groups) reported for the included studies investigating minocycline (listed by frequency).

Minocycline			
	RCTs		**OLTs**
	(Leigh et al., 2013)		(Paribello et al., 2010; Utari et al., 2010)
	Drug	**Plc**	**Drug**
Total N	**33**	**33**	**70**
	n (%)	**n (%)**	**n (%)**
Serious adverse events			
-	-	-	-
Adverse events			
Diarrhoea	15 (45.5)	15 (45.5)	3 (4.3)
Skin rash	12 (36.4)	7 (21.2)	-
Gastrointestinal distress	9 (27.3)	15 (45.5)	18 (25.7)
Fever	6 (18.2)	11 (33.3)	-

Discoloration of teeth	5 (15.2)	-	-
Headache	4 (12.1)	5 (15.1)	2 (2.9)
Sunburn/sun sensitivity	4 (12.1)	1 (3.0)	-
Blue-grey hue to teeth or other tissues	3 (9.0)	1 (3.0)	-
Daytime drowsiness	2 (6.1)	3 (9.0)	-
Increased appetite	2 (6.1)	1 (3.0)	-
Insomnia	2 (6.1)	-	-
Dark coloured urine	1 (3.0)	2 (6.1)	-
Dizziness	-	1 (3.0)	4 (5.7)
Infection	-	-	2 (6.1)

Abbreviations: OLTs: O-label trials; Plc: placebo; RCTs: randomized controlled trials.

Table S4

Rates of serious adverse events (all) and adverse events (at least 5 % in one of the study groups) reported for the included studies investigating modafinil (listed by frequency).

Modafinil		
	RCTs	
	(Wigal et al., 2006)	
	Drug	**Plc**
Total N	**420**	**215**
	n (%)	**n (%)**
Serious adverse events		
Asthma	1 (0.2)	-
Dehydration	1 (0.2)	-
Duodenitis	1 (0.2)	-
Erythema multiforme	1 (0.2)	-
Hypertonia	1 (0.2)	-
Influenza syndrome	1 (0.2)	-
Peptic ulcer	1 (0.2)	-
Possible Stevens-Johnson syndrome	1 (0.2)	-
Adverse events		
Insomnia	115 (27.4)	9 (4.2)
Headache	82 (19.5)	28 (13.0)
Decreased appetite	67 (16.0)	6 (2.8)
Infection	46 (11.0)	1 (0.5)
Abdominal pain	40 (9.5)	-
Increased cough	32 (7.6)	-
Rhinitis	31 (7.4)	-
Pharyngitis	30 (7.1)	-
Fever	21 (5.0)	-
Vomiting	21 (5.0)	-

Abbreviations: Plc: Placebo; RCTs: Randomized controlled trials.

Table S5

Rates of serious adverse events (all) and adverse events (at least 5 % in one of the study groups) reported for the included studies investigating N-acetylcysteine (listed by frequency).

N-Acetylcysteine		
	RCTs	
	(Bloch et al., 2013) (Ghanizadeh et al., 2013), (Ghanizadeh & Moghimi-Sarani, 2013)	
	Drug	**Plc**
Total N	**51**	**44**
	n (%)	**n (%)**
Serious adverse events		
-	-	-
Adverse events		
Nausea	6 (11.8)	12 (27.3)
Constipation	5 (9.8)	1 (2.3)
Increased appetite	5 (9.8)	3 (6.8)
Daytime drowsiness	4 (7.8)	2 (4.5)
Nervousness	4 (7.8)	-
Decreased appetite	3 (5.9)	1 (2.3)
Fatigue	-	6 (13.6)

Abbreviations: Plc: Placebo; RCTs: Randomized controlled trials.

Table S6

Rates of serious adverse events (all) and adverse events (at least 5 % in one of the study groups) reported for the included studies investigating riluzole (listed by frequency).

N-Acetylcysteine			
	RCTs		**OLTs**
	(Ghaleiha, Mohammadi, et al., 2013), (Grant et al., 2014)		(Grant et al., 2007)
	Drug	**Plc**	**Drug**
Total N	**50**	**50**	**6**
	n (%)	**n (%)**	**n (%)**
Serious adverse events			
Pancreatitis	1 (2.0)	-	-
Adverse events			
Increased appetite	12 (24.0)	3 (6.0)	-
Drowsiness	7 (14.0)	4 (8.0)	1 (16.7)
Increased salivation	6 (12.0)	6 (12.0)	-
Abdominal pain	5 (10.0)	2 (4.0)	-
Elevated liver function tests	5 (10.0)	-	2 (33.3)
Restlessness	4 (8.0)	1 (2.0)	-
Nervousness	3 (6.0)	1 (2.0)	-
Vomiting	1 (2.0)	-	1 (16.7)

Abbreviations: OLTs: Open-label trials; Plc: placebo; RCTs: randomized controlled trials.